Three hydrophilic model drugs with different characteristics and molecular weights, namely protamine sulphate, diclofenac sodium and N6-Cyclopentyladenosine (CPA), were nano-encapsulated in poly(d,l-lactide-co-glycolide) (PLGA) using a novel “in-oil nanoprecipitation” method recently developed for the purpose. Although the same settings were used for all three model drugs, the drug loading efficiency was greatly dependent on their chemical–physical characteristics, being considerably higher for protamine (roughly 93%), intermediate for diclofenac (roughly 50%), and very low for CPA (roughly 7%). The resulting particle size and drug release rates were also strictly model-drug dependent. In the attempt to improve the characteristics of the CPA-loaded nanoparticles, the respective effects of adding an excipient (lauric acid) and substituting PLGA with poly(d,l-lactide) polymer (PLA) were investigated by measuring in vitro drug release and drug degradation kinetics in human whole blood. The results indicate that the proposed method seems promising for the nanoencapsulation of hydrophilic drugs in hydrophobic polymers, and easily modifiable to suit molecules that are difficult to incorporate into a polymeric matrix.
|Data di pubblicazione:||2016|
|Titolo:||Application of the "in-oil nanoprecipitation" method in the encapsulation of hydrophilic drugs in PLGA nanoparticles|
|Autori:||Dalpiaz, Alessandro; Sacchetti, Francesca; Baldisserotto, Anna; Pavan, Barbara; Maretti, Eleonora; Iannuccelli, Valentina; Leo, Eliana|
|Digital Object Identifier (DOI):||10.1016/j.jddst.2015.07.020|
|Appare nelle tipologie:||Articolo su rivista|
File in questo prodotto:
|5) Application of the “in-oil nanoprecipitation” method in the encapsulation of hydrophilic drugs in PLGA nanoparticles.pdf||Versione editoriale||Administrator Richiedi una copia|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris